GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Grail GRAL · USD

Health Care · US listing · 🇺🇸 United States

Compare

99.25

-5.33%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Grail — daily GRAL Delayed
Market value
$3.87bn
Last close × shares
Volume
758k
Shares, 20 Nov 2026

About Grail

From its filings with the US Securities and Exchange Commission

SEC filings

Grail is based in Sunnyvale, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker GRAL. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $147.2m and a net loss of $408.4m. At that date it held total assets of $2.92bn and shareholders' equity of $2.58bn.

In its own words

We are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer. Our multi-cancer early detection test (“Galleri”) can screen for many types of cancer, accurately predicting the specific organ or tissue type where the cancer signal originated (the “Cancer Signal of Origin”, or “CSO”), with high positive predictive values (“PPV”) and low false positive rates, all from a simple blood draw. Galleri has detected some of the most aggressive cancers in early stages including, among others, endometrial, esophageal, gastrointestinal, head and neck, liver, pancreatic, and rectal cancers. We have conducted what we believe is the largest clinical program in genomic medicine to date with data from over 385,000 participants that we believe demonstrate the clinical validation and clinical utility of Galleri in its intended use population. We have deep operational experience with over 800,000 tests processed across this clinical program and from our commercial experience, including through partnerships with leading healthcare systems, employers, digital health platforms, payors, and life insurance providers.

Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗

More about Grail →

Latest on Grail

Our reporting

Next results

18 Feb 2027

Due on 18 Feb 2027. Analysts expect earnings of -2.38 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Grail's ticker?

Grail trades as GRAL on its US listing, under ISIN US3847471014.

What was Grail's last closing price?

99.25 on 20 Nov 2026. The figure is in USD and is never converted.

When does Grail next report results?

Results are expected on 18 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.